Development of Anti-OSCAR Antibodies for the Treatment of Osteoarthritis

Gyeong Min Kim, Doo Ri Park, Thi Thu Ha Nguyen, Jiseon Kim, Jihee Kim, Myung Ho Sohn, Won Kyu Lee, Soo Young Lee, Hyunbo Shim

Research output: Contribution to journalArticlepeer-review


Osteoarthritis (OA) is the most common joint disease that causes local inflammation and pain, significantly reducing the quality of life and normal social activities of patients. Currently, there are no disease-modifying OA drugs (DMOADs) available, and treatment relies on pain relief agents or arthroplasty. To address this significant unmet medical need, we aimed to develop monoclonal antibodies that can block the osteoclast-associated receptor (OSCAR). Our recent study has revealed the importance of OSCAR in OA pathogenesis as a novel catabolic regulator that induces chondrocyte apoptosis and accelerates articular cartilage destruction. It was also shown that blocking OSCAR with a soluble OSCAR decoy receptor ameliorated OA in animal models. In this study, OSCAR-neutralizing monoclonal antibodies were isolated and optimized by phage display. These antibodies bind to and directly neutralize OSCAR, unlike the decoy receptor, which binds to the ubiquitously expressed collagen and may result in reduced efficacy or deleterious off-target effects. The DMOAD potential of the anti-OSCAR antibodies was assessed with in vitro cell-based assays and an in vivo OA model. The results demonstrated that the anti-OSCAR antibodies significantly reduced cartilage destruction and other OA signs, such as subchondral bone plate sclerosis and loss of hyaline cartilage. Hence, blocking OSCAR with a monoclonal antibody could be a promising treatment strategy for OA.

Original languageEnglish
Article number2844
Issue number10
StatePublished - Oct 2023

Bibliographical note

Publisher Copyright:
© 2023 by the authors.


  • chondrocyte
  • disease-modifying osteoarthritis drugs
  • human antibody
  • osteoarthritis


Dive into the research topics of 'Development of Anti-OSCAR Antibodies for the Treatment of Osteoarthritis'. Together they form a unique fingerprint.

Cite this